The Cambridge Partnership is the only professional services company in the UK exclusively dedicated to supporting companies in the biotechnology industry. We specialize in providing a “one-stop shop” for accountancy, company secretarial, IP management and admin services.
The Cambridge Partnership was founded in 2012 to fill a gap. Running a biotechnology company has little in common with most “old economy” businesses – the demands of international Venture Capital firms as investors, and surviving entirely on equity investment instead of revenues, provide some unique challenges.
“And the seismic shift towards asset-centric investing and virtual biotech companies that we have pioneered at Index Ventures left us searching for a professional services company that understood the biotech business” said David Grainger, Partner at Index. “The answer was The Cambridge Partnership”.
The Cambridge Partnership, based on the Babraham Research Campus, provides the complete suite of back-office services to allow a biotech company to run smoothly – even a virtual drug development outfit with few, if any, employees. We provide accounting services (including book-keeping, payment runs, payroll, VAT, annual accounts, management accounts, budget forecasts and more), company secretarial services (maintaining company books, Companies House filings and so forth), intellectual property management and a full range of administration services, including HR support. All with a dedicated focus on the biotechnology sector.
For a fixed monthly fee, we take care of every aspect of keeping the business running efficiently, leaving your staff free to do what they do best: developing drugs to build shareholder value.
If you are a UK company, based anywhere in the United Kingdom, get in touch today to discuss your needs, and join more than a dozen other biotechnology companies who rely on The Cambridge Partnership
RxCelerate Ltd is an outsourced drug development platform based near Cambridge, UK. We specialize in delivering an entire road map of drug development services from discovery and medicinal chemistry through to formal preclinical development and clinical up to Phase IIa. In the last five years, we have witnessed dramatic changes in the drug development …